Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism

SUPPLEMENTARY MATERIALS Supplementary material (Appendix)
This supplement contains details regarding the combinations showing joint Bliss and Loewe synergy or antagonism in the different model systems ( Supplementary  Figures 1-6 ). The first Supplementary Figure 1 is discussed in some detail in order to explain how the remaining Supplementary Figures 2-6 should be analyzed in the same manner although the same kind of detailed discussion is not provided for them. Supplementary Table  1 shows the summary of Bliss and Loewe individual synergy analyses for the 15 combinations tested in 6 cell lines and Table 2 shows the summary results of Bliss and Loewe antagonism analyses.
S1: Details regarding combinations showing joint Bliss and Loewe synergy or antagonism in HCT116
Four combinations, shown in the first column of Supplementary Figure 1 are found to be synergistic (panels A-D) or antagonistic (panels E-H) according to the joint Bliss and Loewe analysis. They are represented by the solid lines in Figure 1 in the main text. Each combination has two detailed figures, one on the left (2nd column) corresponding to Bliss analysis and one on the right (3rd column) corresponding to Loewe analysis of same experimental data. More specifically, panels A, C, E and G present the Bliss analyses and panels B, D, F and H present the de-convoluted graphs of Loewe analyses for combinations erlotinib + irinotecan, VLX600 + oxaliplatin, erlotinib + sunitinib and sunitinib + 5FU, respectively. For example in panel A, Bliss analysis results for the HCT116 cell line after exposure to erlotinib and irinotecan are shown. Each vertex in panel A corresponds to a concentration combination; yellow-red spots (peaks) represent synergy (non-overlapping 95% BIs) while cyan-blue spots (depressions) represent antagonism (nonoverlapping 95% BIs). All concentration pairs with 95% BIs covering zero are colored green (zero). The color bar on the right reflects the synergy index defined in (3). Thus, in panel A, the combination erlotinib and irinotecan produces a prominent synergistic spot at 64-128μM of irinotecan and 25-100μM of erlotinib, while spot of synergy values in panel B (Loewe analysis of same data) was found at 16-128μM of irinotecan and 12.5-100μM of erlotinib.
The I max (see section of COMBIA calculations for details) for panel A is 28.7 and the corresponding BI is (7.1, 14.3). For panel B, I max is 41.2 with the corresponding BI (4.6, 9.3). Since in both cases, the observed I max values are much greater than the upper bounds on the respective BIs, synergy is said to be detected according to both Bliss and Loewe global synergy analyses. This is represented by a solid line in Figure 1 of the main text. Similarly, the combination VLX600 + oxaliplatin was also synergistic while the other two combinations erlotinib + sunitinib and sunitinib + 5FU show antagonism according to the same global analysis. 
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Each element in the table, which corresponds to one particular drug combination, cell line and synergy calculation model, is marked by "O" when there exists antagonism (occurs when bootstrap interval of I min does not include observed I min ).
